About this event
This panel discussion will cover the following learning objectives:
- Discover the changes with the new administration & executive orders impacting life sciences & drug development
- Discuss how these changes impact new and ongoing clinical trials both in the USA and with global trials
- Review how these changes impact FDA regulatory review timelines, market access & reimbursement, investments into life sciences, and women’s health and DEI initiatives